CLINICAL TRIALS PROFILE FOR MELOXICAM
✉ Email this page to a colleague
All Clinical Trials for Meloxicam
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00034853 ↗ | Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA) | Completed | Boehringer Ingelheim | Phase 3 | 2000-12-01 | To obtain safety, efficacy, pharmacokinetic and dosing information for meloxicam oral suspension in children with Juvenile Rheumatoid Arthritis (JRA) |
| NCT00042068 ↗ | A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis | Completed | Boehringer Ingelheim | Phase 3 | 2002-06-01 | A 12-week trial consisting of 5 visits (6 if follow up is needed) to find out how effective and safe three different doses of meloxicam are compared with placebo in Rheumatoid Arthritis. Patient will take one dose of study medication daily. |
| NCT00152919 ↗ | Mobicox: Study of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy | Completed | Princess Margaret Hospital, Canada | Phase 3 | 2004-02-01 | Swelling of the prostate can occur during and after a brachytherapy. This swelling can cause urinary problems ranging from difficulty voiding to urinary retention. The purpose of this study is to investigate whether Mobicox started one week before brachytherapy and then continued afterwards is more effective in reducing the risk of needing a catheter than Mobicox given only afterwards. |
| NCT00152919 ↗ | Mobicox: Study of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy | Completed | University Health Network, Toronto | Phase 3 | 2004-02-01 | Swelling of the prostate can occur during and after a brachytherapy. This swelling can cause urinary problems ranging from difficulty voiding to urinary retention. The purpose of this study is to investigate whether Mobicox started one week before brachytherapy and then continued afterwards is more effective in reducing the risk of needing a catheter than Mobicox given only afterwards. |
| NCT00239382 ↗ | A Study to Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily in Patients With Rheumatoid Arthritis | Completed | Boehringer Ingelheim | Phase 3 | 2004-07-01 | The objective of this trial was to assess the efficacy and safety of 15 mg meloxicam i.m. once daily compared with 15 mg meloxicam tablets once daily p.o. in patients with Rheumatoid arthritis over a time period of 7 days. |
| NCT00239395 ↗ | A Study to Compare Meloxicam IM Once Daily and Meloxicam Administered Orally Once Daily in Patients With Osteoarthritis | Completed | Boehringer Ingelheim | Phase 3 | 2004-07-01 | The objective of this trial was to assess the efficacy and safety of 7.5 mg meloxicam i.m. once daily compared with 7.5 mg meloxicam tablets once daily p.o. in patients with osteoarthritis over a time period of 7 days. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Meloxicam
Condition Name
Clinical Trial Locations for Meloxicam
Trials by Country
Clinical Trial Progress for Meloxicam
Clinical Trial Phase
Clinical Trial Sponsors for Meloxicam
Sponsor Name
